FDA advisers say risks of GSK blood cancer drug outweigh benefits in surprise setback
STAT   2 days ago
Read Full Story
FDA advisers say risks of GSK blood cancer drug outweigh benefits in surprise setback  STATFDA Committee Votes Against GSK Blood Cancer Drug Blenrep  The Wall Street JournalFDA’s ODAC Votes Against Risk:Benefit Profiles of Belantamab Mafodotin...